{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["Xie K"],"pubmed_abstract":["<h4>Background</h4>Vitamin D deficiency (VDD) is a worldwide disease. VDD is also associated with an increased risk of HIV-related comorbidities and mortality, and patients have a tendency to develop active tuberculosis compared to those with latent tuberculosis infection. Vitamin D supplementation may modulate HIV replication, improve TB inflammation and reduce progression of HIV-TB co-infection.<h4>Methods</h4>We meta-analyzed individual participant data from cohort studies, cross-sectional study, and RCTs of vitamin D in HIV group, TB group, and HIV-TB group. The primary outcomes were differences in vitamin D level and VDD prevalence between three groups, the secondary outcomes were CD4 count, HIV viral load, time to sputum smear conversion, time to culture conversion, relapse, morality, and TB score.<h4>Results</h4>For vitamin D levels, the overall mean difference (MD) between HIV group and TB group was -0.21 (95% CI, -20.80-20.38; <i>p</i> = 0.9, <i>I</i><sup>2</sup> = 84%), HIV group and HIV-TB group was 0.87 (95% CI, -11.45-13.20; <i>p</i> = 0.89, <i>I</i><sup>2</sup> = 87%), and TB group and HIV-TB group was 1.17 (95% CI, -5.21-7.55; <i>p</i> = 0.72, <i>I</i><sup>2</sup> = 85%). For vitamin D deficiency prevalence, the overall odds ratio (OR) for HIV group versus TB group was 1.23 (95% CI, 0.46-3.31; <i>p</i> = 0.68; <i>I</i><sup>2</sup> = 70%), HIV group versus HIV-TB group was 1.53 (95% CI, 1.03-2.29; <i>p</i> = 0.04; <i>I</i><sup>2</sup> = 0%), and TB group versus HIV-TB group was 0.85 (95% CI, 0.61-1.20; <i>p</i> = 0.36; <i>I</i><sup>2</sup> = 22%). In HIV-TB group, the overall OR for vitamin D group versus placebo group was 0.78 (95% CI, 0.34-1.67; <i>p</i> = 0.52; <i>I</i><sup>2</sup> = 60%).<h4>Conclusion</h4>Our findings indicated that there were no variations in vitamin D levels between three groups. The prevalence of vitamin D deficiency was higher in the HIV-TB group than in the HIV group. Additionally, the administration of vitamin D supplements did not have obvious impact on CD4 count and viral load. Likewise, vitamin D had no effect on time to sputum smear conversion, time to culture conversion, relapse, 12-month morality, and TB score."],"journal":["Frontiers in public health"],"pagination":["1344024"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10910524"],"repository":["biostudies-literature"],"pubmed_title":["Association of vitamin D with HIV infected individuals, TB infected individuals, and HIV-TB co-infected individuals: a systematic review and meta-analysis."],"pmcid":["PMC10910524"],"pubmed_authors":["Li Z","Zhang T","Xie K","Zhang Y","Zheng L","Zhang M","Ji J","Wang W","Wu H"],"additional_accession":[]},"is_claimable":false,"name":"Association of vitamin D with HIV infected individuals, TB infected individuals, and HIV-TB co-infected individuals: a systematic review and meta-analysis.","description":"<h4>Background</h4>Vitamin D deficiency (VDD) is a worldwide disease. VDD is also associated with an increased risk of HIV-related comorbidities and mortality, and patients have a tendency to develop active tuberculosis compared to those with latent tuberculosis infection. Vitamin D supplementation may modulate HIV replication, improve TB inflammation and reduce progression of HIV-TB co-infection.<h4>Methods</h4>We meta-analyzed individual participant data from cohort studies, cross-sectional study, and RCTs of vitamin D in HIV group, TB group, and HIV-TB group. The primary outcomes were differences in vitamin D level and VDD prevalence between three groups, the secondary outcomes were CD4 count, HIV viral load, time to sputum smear conversion, time to culture conversion, relapse, morality, and TB score.<h4>Results</h4>For vitamin D levels, the overall mean difference (MD) between HIV group and TB group was -0.21 (95% CI, -20.80-20.38; <i>p</i> = 0.9, <i>I</i><sup>2</sup> = 84%), HIV group and HIV-TB group was 0.87 (95% CI, -11.45-13.20; <i>p</i> = 0.89, <i>I</i><sup>2</sup> = 87%), and TB group and HIV-TB group was 1.17 (95% CI, -5.21-7.55; <i>p</i> = 0.72, <i>I</i><sup>2</sup> = 85%). For vitamin D deficiency prevalence, the overall odds ratio (OR) for HIV group versus TB group was 1.23 (95% CI, 0.46-3.31; <i>p</i> = 0.68; <i>I</i><sup>2</sup> = 70%), HIV group versus HIV-TB group was 1.53 (95% CI, 1.03-2.29; <i>p</i> = 0.04; <i>I</i><sup>2</sup> = 0%), and TB group versus HIV-TB group was 0.85 (95% CI, 0.61-1.20; <i>p</i> = 0.36; <i>I</i><sup>2</sup> = 22%). In HIV-TB group, the overall OR for vitamin D group versus placebo group was 0.78 (95% CI, 0.34-1.67; <i>p</i> = 0.52; <i>I</i><sup>2</sup> = 60%).<h4>Conclusion</h4>Our findings indicated that there were no variations in vitamin D levels between three groups. The prevalence of vitamin D deficiency was higher in the HIV-TB group than in the HIV group. Additionally, the administration of vitamin D supplements did not have obvious impact on CD4 count and viral load. Likewise, vitamin D had no effect on time to sputum smear conversion, time to culture conversion, relapse, 12-month morality, and TB score.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2025-04-26T22:34:37.761Z","creation":"2025-04-06T17:14:35.61Z"},"accession":"S-EPMC10910524","cross_references":{"pubmed":["38439754"],"doi":["10.3389/fpubh.2024.1344024"]}}